Conflicts of interest and associated conduct risks during the equity capital raising process

Consultation Report

The Board
OF THE
INTERNATIONAL ORGANIZATION OF SECURITIES COMMISSIONS

CR02/2018 February 2018

This paper is for public consultation purposes only. It has not been approved for any other purpose by the IOSCO Board or any of its members.
Foreword

The Board of the International Organization of Securities Commissions (IOSCO) has published this Consultation Report with the aim of proposing Guidance to help IOSCO members address the potential conflicts of interest and associated conduct risks in the equity capital raising process. The proposed Guidance reflects an expectation of high standards of conduct by market intermediaries in the equity capital raising process. Although the proposed Guidance is non-binding, IOSCO encourages its members to consider the extent to which this guidance should be implemented in the context of their legal and regulatory framework, given the significance of the associated risks.

How to Submit Comments

Comments may be submitted by one of the three following methods on or before 4 April 2018. To help us process and review your comments more efficiently, please use only one method.

Important: All comments will be made available publicly, unless anonymity is specifically requested. Comments will be converted to PDF format and posted on the IOSCO website. Personal identifying information will not be edited from submissions.

1. Email
   • Send comments to consultation-02-2018@iosco.org
   • The subject line of your message must indicate ‘Consultation report on conflicts of interest and associated conduct risks during the equity capital raising process’
   • If you attach a document, indicate the software used (e.g., WordPerfect, Microsoft WORD, ASCII text, etc) to create the attachment.
   • Do not submit attachments as HTML, PDF, GIFG, TIFF, PIF, ZIP or EXE files.

2. Facsimile Transmission

Send by facsimile transmission using the following fax number: +34 (91) 555 93 68.

3. Paper

Send three (3) copies of your paper comment letter to:

Alp Eroglu
International Organization of Securities Commissions (IOSCO)
Calle Oquendo 12
28006 Madrid
Spain

Your comment letter should indicate prominently that it is a ‘Public comment on the consultation report on conflicts of interest and associated conduct risks during the equity capital raising process’
## Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>[no.] Chapter 1 – Executive Summary</td>
<td>1</td>
</tr>
<tr>
<td>[no.] Chapter 2 – Background and scope</td>
<td>3</td>
</tr>
<tr>
<td>[no.] Chapter 3 – Description of the equity capital raising process</td>
<td>5</td>
</tr>
<tr>
<td>[no.] Chapter 4 – Potential risks and harms identified in the equity capital</td>
<td>9</td>
</tr>
<tr>
<td>[no.] Chapter 5 – Proposed IOSCO Guidance</td>
<td>15</td>
</tr>
<tr>
<td>[no.] Chapter 6 – Conclusions and next steps</td>
<td>22</td>
</tr>
</tbody>
</table>
Chapter 1 - Executive Summary

Capital markets play a vital role in the global economy. Effective capital markets are dependent on high standards of conduct within intermediaries. However, in the capital raising process itself, intermediaries may encounter conflicts of interests which, if not appropriately managed, can compromise the integrity and efficiency of the process. This can make capital markets a less effective route for issuers to raise finance.

In August 2017, the IOSCO Board approved a mandate for Committee 3 on Regulation of Market Intermediaries (C3) to examine conflicts of interest and associated conduct risks in the capital raising process. The work to be undertaken under the mandate is divided into two stages. The first stage focuses on the equity capital raising process, which is the subject of this Consultation Report. The second phase will consider conflicts of interest and associated conduct risks during the debt capital raising process. The mandate was a recognition that in some member jurisdictions, notwithstanding existing IOSCO guidance and existing rules, poor conduct practices may still exist, potentially impairing the integrity and efficiency of capital markets.

Conflicts of interest and associated conduct risks identified

A survey of C3 members reflected that conflicts of interest and associated conduct risks in the equity capital raising process were present in some jurisdictions. The following key risks were identified:

• Conflicts of interest and pressures on ‘connected analysts’ during the formation of their views on an issuer in the pre-offering phase of a capital raising;
• The prominence of conflicted connected research during investor education and price formation in equity IPOs; and
• Conflicts of interest during the allocation of securities.

The following additional risks were also present in some C3 jurisdictions:

• Management of underwriting risk by firms managing the offering and associated conflicts of interest in the pricing of securities; and
• Conflicts associated with personal transactions by staff employed within firms managing the offering.

Proposed IOSCO Guidance

This Consultation Report proposes Guidance to IOSCO members to address the identified risks. The Guidance, combined with a package of measures (hereinafter “Guidance”), reflects an expectation of high standards of conduct by market intermediaries in the equity capital

---

1 Some members reported that they have existing controls for conflicts of interest and associated conduct risks within their legal and regulatory regime that mitigate the concerns raised in this Consultation Report. As a result, the Guidance contained in this report may not be appropriate for, or permitted under, the specific legal and regulatory framework of each member.

2 Connected analysts are those employed within firms managing the securities offering.

3 Connected research is research produced by connected analysts.
raising process. Although the Guidance in the box below are not binding, given the significant potential risks and harms they are intended to address, IOSCO members are encouraged to consider these proposals carefully in the context of their legal and regulatory framework.

### Proposed IOSCO Guidance

**Measure 1:** In the context of pitches to secure a mandate to manage an equities securities offering, regulators should consider requiring firms to take reasonable steps to prevent their analysts from coming under pressure to take a favourable view on the offering from the issuer’s representatives.

**Measure 2:** Regulators should consider requiring that, once an underwriting or placing mandate has been awarded, firms take the reasonable steps to prevent a connected analyst’s views and research on the equities securities offering from being improperly influenced and to ensure that the analyst remains objective.

**Measure 3:** Regulators should consider requiring that, once an underwriting or placing mandate has been awarded, firms have appropriate controls to manage potential conflicts of interest and associated conduct risks arising from connected analysts performing an internal advisory role within the firm in the context of an equity securities offering.

**Measure 4:** Regulators should consider requiring firms to support the provision of a wide range of independent information to investors in a timely manner, where distribution of such information is permitted under local law.

**Measure 5:** Regulators should consider requiring firms to maintain an allocation policy that sets out their approach for determining allocations and that provides the issuer with an opportunity to express their preference during the process.

**Measure 6:** Regulators should consider requiring firms to maintain records of the allocation decisions to demonstrate that any conflicts of interest are appropriately managed.

**Measure 7:** Regulators should consider requiring firms to manage any conflicts of interest that arise in relation to pricing an equity securities offering, keep the issuer informed of key decisions or actions which can influence pricing outcome, and give the issuer an opportunity to express preference regarding the pricing of an issue during the pricing process.

**Measure 8:** In the context of a securities offering, regulators should consider requiring firms to prevent any employees who have access to confidential information on the issuer from entering into or causing any personal transactions in situations where it involves misuse or improper disclosure of the confidential information. Regulators should also consider requiring firms to prevent any employees from entering into personal transactions where it otherwise gives rise to any conflicts of interest.
Chapter 2- Background and scope

Conflicts of interest and associated conduct risks stemming from the role of intermediaries during the capital raising process can threaten its integrity and efficiency, reduce investor confidence, and impair the effectiveness of the capital markets as a route to support the funding needs of a large number of key participants in the global economy.

Previous IOSCO work in this area

IOSCO had previously considered conflicts of interest for sell-side analysts and related issues. In 2003, IOSCO released a Statement of Principles on analyst conflicts of interest\(^4\) in both primary and secondary markets. The Statement recognised that the flow of timely and accurate information about issuers and securities is fundamental to ensuring fair, efficient and transparent markets, and that analysts can provide valuable insights to investors and assist them in making an investment decision. It also recognised that the integrity and objectivity of analysts is of crucial importance. The Statement sets out some principles and measures for regulators to implement domestically, following an earlier report which identified the risk of potential conflicts of interest.

In 2007 IOSCO published a report on conflicts of interest in securities offerings.\(^5\) The report set out general guidelines for regulators and market participants when considering how to address conflicts of interest that may occur when firms manage securities offerings.

New IOSCO mandate

Notwithstanding the earlier IOSCO work, the UK FCA\(^6\) and ASIC\(^7\) found evidence that, in their jurisdictions, conflicts of interest and associated misconduct were still present at various stages in the capital-raising process. Collectively, the key findings were:

- Conflicts of interest during the production of connected research\(^8\) on equity IPOs;
- Prominence of conflicted connected research throughout ‘investor education’ and price formation during equity IPOs;
- Conflicts of interest during the allocation of securities.

In light of these findings, C3 identified the need for the new mandate. While building on the earlier IOSCO work, the new mandate addresses the potential harm caused by specific,
existing conflicts of interest and associated misconduct which can arise during the capital raising process.

The mandate aligns with IOSCO’s core overarching objectives since it is intended to:

• Enhance investor confidence in the integrity of the capital raising process and improve the efficiency of the process by serving as a route for issuers to raise finance;
• Improve cooperation between C3 members and the exchange of information at a global level on their respective experiences in relation to the capital raising process in order to assist the development of markets and implement appropriate regulation.

Implementation of the new IOSCO mandate

A Working Group of C3 members was established to progress the work under the mandate. The Working Group comprises ASIC, the UK FCA, HK SFC, Japanese FSA, IIROC, and the US SEC.

The Working Group conducted a survey of C3 members to gather detailed information on the equity capital raising process across different jurisdictions. The survey sought to identify the key stages involved in a typical capital raising, the regulatory and legal framework governing that process, and any conflicts of interest and associated misconduct risk that might arise at various stages of the process. The survey covered both equity IPOs and secondary equity offerings.

Drawing on the information gathered through this survey, C3 has identified aspects of market practice across different jurisdictions which could potentially result in conflicts of interest and related conduct risk in the equity capital raising process, including in relation to the role of connected analysts in the process, the prominent role that connected research plays in investor education and price formation, and allocations of securities. This has resulted in a package of proposed IOSCO Guidance with measures designed to address the potential risks and harm identified.
Chapter 3- Description of the equity capital raising process

This section provides a general description of the equity capital raising process and is based on responses to the member survey. While the process as described is not uniform across all member jurisdictions, it serves as an example to highlight key stages of the equity capital raising process where conflicts of interest are likely to arise. Although the main focus is on equity IPOs, C3 identifies any material differences in a secondary offering context.

A description of key participants in an equity capital raising process are summarised in Annex 1. A general description of the regulatory and legal frameworks for an equity capital raising process in some jurisdictions is set out in Annex 2, but is briefly summarised in this section.

The equity capital raising process

In those C3 member jurisdictions that collect investor profile statistics, the majority of equity IPOs are targeted primarily at institutional investors, with limited direct retail participation. Specifically, in such jurisdictions, retail investors as a proportion of the overall investor base, range between 6% and 40% with the majority being around 20-25%.9

The likelihood of an equity IPO including a retail component typically depends on a number of factors such as the size and sector of the issuer, the preference of the issuer’s management, the class structure of the equity shares being offered, and the retail investor ownership for peer issuers in the same sector.

In broad terms, the equity IPO process may be seen as comprising two stages, namely a ‘pre-offering’ phase and an ‘offering’ phase. These are described in turn below.

Figure 1: An equity IPO process10

9 Based on survey responses from securities regulators in Saudi Arabia, Hong Kong, the Netherlands, Switzerland, Pakistan, the United Kingdom, Spain, Singapore, Romania, France, Turkey, Australia, Canada, Japan and Germany.

10 Note that this diagram is not representative of the IPO process in all IOSCO jurisdictions.
Pre-offering phase\textsuperscript{11}

Using the example above (see Figure 1), prior to making a decision to pursue an IPO, the issuer may meet with prospective institutional investors to inform them on the company and gauge interest in any transaction, i.e. a “market sounding”. These soundings can also take place at a later stage, once firms have been appointed to the syndicate to act in the IPO.

In some jurisdictions, the issuer’s management may meet analysts of the firm before issuing a mandate. These meetings may be used by the issuer to gain an understanding of the analyst’s views on the sector and its prospects. The issuer’s shareholders and independent corporate finance advisers to the issuer may also be present. Analysts can also use these meetings to support an internally-facing ‘vetting’ and ‘due diligence’ advisory service to their firm. This may involve the analyst contributing their specialist knowledge of the industry sector, which may be taken into account by the firm in their decision on whether to pitch for a mandate to manage an offering.

Once the issuer has awarded the firm with a mandate to manage the offering, it is also common in some jurisdictions for the issuer’s management to give an ‘analyst presentation’ to connected analysts. This presentation contains information on the issuer that is to be included in the prospectus or offering document, and will help connected analysts develop views on the offering and to prepare their research.

Also after the mandate has been awarded, an analyst may perform an internal advisory role to the firm to help it determine the extent to which any risks emerge as the transaction evolves.

Offering phase\textsuperscript{12}

Some respondents to the survey of C3 members indicated that the offering phase begins with a public announcement of the transaction. In Hong Kong, Australia and the UK, for example, the announcement is accompanied by the release of connected research to selected institutional investors. By contrast, Pakistan and the US, for example, prohibit the publication of written connected research during the IPO process (for the US, unless an exemption under the JOBS Act is available). In fact, in the US, the Financial Industry Regulatory Authority’s (FINRA) rules generally prohibit firms from publishing connected research on the issuer for a defined period following the commencement of certain offerings.\textsuperscript{13}

\textsuperscript{11} In this example, the pre-offering phase refers to the period prior to the formal offering of securities during which, for example, issuers and/or intermediaries may, depending on what is permitted in the member jurisdiction, seek market soundings or initial soundings of prospective investors, award mandates, reach out to cornerstone investors, provide ‘early-look’ or ‘pilot-fishing’, make analyst presentations, and publicly announce a transaction. An ‘analyst presentation’ is a presentation from the issuer’s management to connected analysts, containing information on the company based on material to be included in the prospectus or official offering document.

\textsuperscript{12} In this example, the offering phase refers to the period following the announcement of the offering, including, for instance, publication of the draft and/or final offering document/prospectus, management roadshows, book-building and pricing of the offering.

\textsuperscript{13} There are certain exemptions to these restrictions for emerging growth companies in the US. An emerging growth company is defined in the US as an issuer with total annual gross revenues of less than $1.07 billion during its most recently completed fiscal year.
Responses also suggested that in some jurisdictions there will be a period, typically lasting two
weeks, during which connected analysts use their research to provide investors with their views
on the issuer, in a process known as investor education.

Several respondents suggested that a price range is then circulated to certain institutional
investors alongside a draft prospectus or offering document.

Some responses suggested that, once a prospectus or offering document (may be in draft or
final form) is released, the issuer’s management and firms managing the offering will stage a
management roadshow, typically lasting two weeks. During this roadshow book-building will
usually take place, after which a final offer price will be determined and shares will be allocated
to investors.

**Secondary offerings**

Secondary offerings can include rights issues, open offers, placings, and block trades. Shares
issued in a rights issue are typically made available to existing shareholders, though this is not
necessarily the case in open offers, placings and block trades. Some C3 members acknowledged that this pro-rata allocation avoids dilution in the value of shareholdings.

Research on a secondary offering is likely to play a different role to connected research on an
IPO. The secondary offering research would be based on publicly available information on the
company and would be more widely distributed, similar to the role of research in a secondary
market context. Another difference in the process between IPOs and secondary offerings is that
no roadshows are conducted.

An additional key difference is pricing. In the case of an IPO, significant emphasis is placed
on price discovery during the investor education phase and book-build. However, during a
secondary offering, the issuer already has shares admitted to trading that are priced on the
secondary market, which form the basis of pricing the secondary offering.

The length and the general sequencing of key events during the offering phase in IPOs and
secondary offerings may also be different across jurisdictions. Some responses suggest that the
process for a block trade is much simpler than an IPO and there would be no investor education
or management roadshows involving analysts in the former. Some secondary offerings take
place in the form of an accelerated book-build, with the whole process taking place very
quickly.

The UK FCA indicated that, subject to exemptions under the EU prospectus regime (see ‘legal
and regulatory frameworks governing the capital raising process’), rights issues in the UK
would typically involve a prospectus but a placing may not and that, where a prospectus is
produced, it would typically be available earlier in the process than it currently is during an
IPO. IIROC noted that, in Canada, secondary offerings typically involve a short-form
prospectus, which requires less due diligence by firms managing the offering, largely because
the issuer is subject to continuous disclosure obligations in relation to its listed securities.

**Legal and regulatory frameworks governing the capital raising process**

There are a variety of regulatory and legal frameworks across different jurisdictions which
govern the capital raising process. Some jurisdictions have a general overarching regulatory
regime which addresses conflicts of interest and relies on this for guidance on how conflicts of interest arise in the context of a securities offering.

Some C3 members have requirements in relation to the production and distribution of research, intended to preserve the independence of analysts, including during their role in a securities offering. For example, in some jurisdictions, analysts are prohibited for participating in pitches for new investment banking business.

Most C3 members have specific rules governing the provision of information during a securities offering. These include rules on the timing and content of information included in the prospectus, which issuers are required to publish ahead of their shares being admitted to trading, as well as requirements on firms to prevent the flow of confidential and price sensitive information between investment banking staff providing services to an issuer client, and other areas of the firm.

While some jurisdictions have more general rules in place to promote investor confidence and to protect against certain misconduct in the way securities are allocated to investors, other jurisdictions have targeted regulatory requirements for the allocations process. These vary greatly across jurisdictions, but range from the requirement for firms to maintain an allocation policy and for allocations to be fair, equitable and transparent, to measures intended to ensure retail participation in IPOs. At the EU level, MiFID II has introduced targeted principles-based provisions governing underwriting and placing services, including conflicts management and disclosure of information requirements in relation to pricing and allocations.

Further detail on the legal and regulatory frameworks across C3 members are set out in Annex 2.
Chapter 4- Potential risks and harms identified in the equity capital raising process

This section sets out the market practices across C3 member jurisdictions identified from survey responses which can create conflicts of interest and associated misconduct risk at each stage of the capital raising process. It also explains how these risks can translate into harm for users of capital markets. Finally, this section considers the extent to which these potential risks and harms should be addressed by existing IOSCO Guidance of relevance to the conduct of intermediaries in securities offerings, or whether additional new IOSCO Guidance is necessary.

The key risks identified are in relation to the following:

- Conflicts of interest and pressures on connected analysts during the formation of their views on an issuer in the pre-offering phase of a capital raising;
- Timing, sequencing and level of information in the offering phase of an equity IPO capital raising, and the prominence of conflicted connected research during investor education and price discovery; and
- Conflicts of interest during the allocation of securities during an offering.

The following additional risks have also been identified, though these are not necessarily common across a wide range of C3 members:

- Management of underwriting risk by firms managing a securities offering and associated conflicts of interest in the pricing of securities; and
- Conflicts of interest associated with personal transactions by staff employed within firms.

Conflicts of interest during the formation of a connected analyst’s views on an issuer in the pre-offering phase of an equity capital raising

It is possible that, when connected analysts are developing their views on an issuer during the pre-offering phase of the process, they could be influenced and be at risk of bias. This can stem from a connected analysts’ interactions with the issuer’s representatives when underwriting or placing mandates are being considered, during the review processes for connected research, and as part of the wider role of connected analysts in the process.

Pressure on connected analysts to have a favourable view on an IPO and secondary offering

In jurisdictions where no prohibition exists, it is generally established practice for an analyst to participate in its firm’s pitches to win a mandate to manage a securities offering. Even if this practice is prohibited, analysts have also been observed to interact with the issuer’s management, independent corporate finance advisers (outside of the firm managing the offering), and shareholders alongside the formal pitching efforts by corporate advisory or investment banking staff within the firm. These are often referred to as ‘vetting’ meetings.

Some C3 members have found that the issuer’s management and/or independent corporate finance advisers (outside of the firm managing the offering) may place pressure on analysts to
take a favourable view on the issuer to help their firm win a mandate to manage the offering. The powerful commercial incentives within the investment bank itself can also further pressure analysts to indicate their support for the issuer. In the UK, once mandates have been awarded, analysts can continue to face pressure to be supportive of the issuer if their bank is to secure its desired position in the syndicate.

The UK FCA has evidence that connected analysts can be pressured by the issuer's management, independent corporate finance advisers or by investment banking staff within firms themselves, to publish a single common view and common forecasts and that this may take place during the factual accuracy checks on the research. Another jurisdiction had seen examples of corporate advisory and investment banking staff within the firm exerting pressure on analysts with respect to valuation information and forecasts, including:

- Suggesting that a peer group with higher valuation multiples be included;
- Re-writing previously published research so it was more favourable to a firm’s commercial interests; and
- Re-writing research to increase revenue forecasts.

In principle, the conflicts of interest and associated misconduct risks which may arise during the formation of a connected analyst’s views on an IPO can also exist in a secondary offering context. For example, although in a secondary offering context it is rare for analysts within firms hoping to manage an offering to interact with the issuer’s representatives around the time that underwriting or placing mandates are being considered, it is still possible that, when producing research on the company (either as part of their on-going coverage of the company in the secondary market, or specifically in relation to the secondary offering itself), connected analysts could be put under pressure to produce a favourable message by the issuer’s representatives or investment banking colleagues within the firm itself. This may be the case even if the connected analyst is unaware that ECM colleagues are pitching for the underwriting or placing mandate.

**Wider role of connected analysts in the equity IPO process**

In some jurisdictions, in addition to preparing research for the purposes of investor education, connected analysts can have two further roles. The first is to support the firm’s ‘vetting’ of the issuer and use information gathered as part of this exercise to provide an internal facing ‘due diligence’ advisory service to the overall firm, prior to underwriting or placing mandates being awarded.

As part of this role, connected analysts may advise on the market’s likely interest in the issuer, assessing the issuer’s operations, board and management, advising on the likely listed peer group and optimum timing for the transaction, and commenting on risks to the issuer or the sector in which it operates. As described above, the vetting meetings with the issuer’s representatives can result in the connected analyst coming under pressure to have a favourable view on the company.

The second is an internal facing on-going due diligence advisory service to the overall firm, which is provided after an underwriting or placing mandate has been awarded. This role can create a conflict of interest because it means that the connected analyst becomes closely linked to the corporate advisory or investment banking function of the firm.
Timing, sequencing and level of information in the offering phase of the equity IPO process

In some jurisdictions, connected analysts share their analysis on the issuer (either in written form or verbally) during the investor education phase with select institutional investors. This often includes forecasts of the company’s future prospects. In some other jurisdictions, term sheets and roadshow materials play a prominent role during investor education for institutional investors. Some jurisdictions prohibit written research reports during this period, and some jurisdictions reported that other information such as the prospectus, website announcements and press articles are available to all investors during this period and that connected analysts do not appear to play a significant role.

However, across a number of jurisdictions, a draft prospectus or offering document containing an initial price range is only available to investors at the end of investor education. The final prospectus containing a final price is released at the conclusion of the offering phase once the book-build is complete.

As such, across a number of jurisdictions, the views of the connected analyst, which are at risk of bias, play a prominent role in investor education and initial price discovery during an equity IPO. This is because the prospectus or offering document is currently made available relatively late in the process. The late availability of a publicly available prospectus, together with a lack of access to the issuer’s management, means that unconnected analysts are unable to access the necessary information to produce unconnected IPO research.

Unconnected research may also be available in situations where the private company is already covered by an independent research provider or where such provider is hired by the issuer to assist in the due diligence and price discovery process (e.g. in Canada). Both instances are reported to be uncommon.

The concerns about connected analysts being the main source of information driving price discovery are less relevant in a secondary offering context. This is largely because the issuer’s shares are already priced on the secondary market and, therefore, price discovery does not happen in the way that it does in an IPO. Moreover, the issuer should make periodic disclosures on key financial information on the company as part of its regulatory filings, which means that there is more official, factual information on the issuer available to investors to perform their own due diligence. Finally, given that all research (including that produced by connected analysts) is likely to be based on publicly available information on the company, there would be less of a barrier preventing unconnected analysts from producing research on the secondary offering.

Conflicts of interest during the allocation of securities

Firms across most jurisdictions generally consider a range of factors when determining the allocations of securities in an IPO. These include: the type, size and ranking of the investor;

---

14 “Unconnected analysts” are those employed within firms who are not managing the offering or by independent research providers. “Unconnected research” means research that is produced and/ or disseminated by those analysts.

15 Recent work by the UK FCA has found that revenues generated to the bank by investors through other business lines are also a factor determining allocation decisions. The UK FCA found that investors in
the timing and receipt of bids; the degree of oversubscription; the investor's engagement with
the firm and whether it has assisted in the price discovery and execution process; the size of
interest the investor has indicated and whether the firm considers that realistic; the issuer’s
preference; and applicable rules or codes of conduct.

Whilst firms in most jurisdictions typically maintain an overarching allocation policy, in
practice they use this policy as guidelines and exercise significant discretion in allocating
securities on a transaction-by-transaction basis. For example, in some jurisdictions, allocations
can be made towards:

(i) A firm’s most valued clients;
(ii) Investors who have contributed to the price discovery process;
(iii) Other parts of the firm’s business (for example, their own asset
management division) or their employees;
(iv) Clients or senior management of the issuer; and
(v) Investors who generate a favourable after market for the shares.

Some of these types of allocation practices may indicate that allocation decisions can be
influenced by conflicts of interest, and that those decisions might advance the firms’ own
interests (or those of its other clients) in a way which could potentially be inconsistent with the
interests of the firm’s issuer client at the relevant time.

Managing underwriting risk by firms managing securities offerings and
associated conflicts of interest in the pricing of securities offerings

Where a firm is providing underwriting services on a firm commitment basis, it may have an
interest in ensuring that all securities are subscribed to by investors. This can mean that the
way in which securities offerings are priced is inconsistent with the interests of the issuer client.

For example, during an equity IPO, a bank may seek to price the offering below its fair market
value (i.e. under-price the offering) to increase the likelihood of a full take-up for the offering
and to avoid having to purchase shares that have not been subscribed by investors. This would
increase the cost of capital for the issuer.

A bank may also engage in a variety of hedging strategies to mitigate their underwriting risk.
Hedging would seek to ensure that the costs of any such purchase would be offset by gains in
another asset or instrument. However, a bank’s hedging strategies may not align with the
interests of the issuer client. For example, in a secondary offering context, a bank may hedge
its underwriting risk by short-selling the existing shares that the issuer has admitted to trading,
which could negatively impact the price of those existing shares and, therefore, the price of the
secondary offering.

the top quartile of the book-runners’ clients by revenue receive allocations, relative to the amount they
bid, approximately 60% higher than those received by investors who are not clients of the book-runner.
Personal transactions by staff employed within firms managing securities offerings

In the context of a securities offering, where employees of a firm undertake personal transactions in the securities of that issuer, they may have an interest in influencing the capital raising process in a way that advances their own interests, but to the detriment of the issuer’s interests. This may be exacerbated where the employees have access to confidential information on the issuer, since there is scope for employees to misuse that information for personal gain.

This potential conflict could occur in an IPO and secondary offering context. For example, during an IPO with a retail component, analysts and investment banking staff within the firm may seek to participate as investors in the transaction. However, they may misuse their professional role on the transaction to advance their personal interests as shareholders of the issuer’s securities.

Moreover, where employees of a firm managing a secondary offering for an issuer have a holding in those securities, they may wish to engage in trading activities to influence the price of the issuer’s existing securities in a way which is potentially contrary to the firm’s issuer client’s interests. This could also, in turn, potentially influence the price of the secondary offering in a way that is inconsistent with the issuer’s interests. In some jurisdictions, there are high levels of personal transactions amongst employees such as investment banking staff and connected analysts in an issuer’s securities, especially within mid-sized firms.

Potential harm in the equity capital raising process

As set out above, conflicts of interest and associated conduct risk can arise at each stage of the equity capital raising process. This can translate into the following broad types of harm to issuers and investors:

- **Threats to the efficiency and integrity of price formation:** The prominence of connected analysts - whose views on the issuer can be biased or perceived as biased - during investor education and initial price discovery, can hamper the efficiency and integrity of price formation during a securities offering. This is particularly the case during equity IPOs where connected analysts are, in some jurisdictions, a main provider of information to investors, but can also be a problem during secondary offerings where a wider range of information may be available. This is exacerbated to the extent that pricing decisions and outcomes are seen to reflect the interest of the bank in a way that conflicts with the interests of the issuer. A reduction in the efficiency and integrity of price formation can impair the effectiveness of capital markets as a route for issuers to raise finance.

- **Reduced confidence in the integrity of allocations:** To the extent that allocations are seen to reflect the interest of the bank and it is not clear whether they are aligned with the issuer’s interests, issuers may lose confidence in the process. Investors may also perceive allocations as lacking transparency and being conflicted, which reduces their confidence in the process and may reinforce the above harm.
Should these risks and harms be addressed by existing IOSCO Guidance?

It is important to consider previous IOSCO work in this area and the extent to which the potential risks and harms identified above are inconsistent with any existing Guidance.

As noted in Section 1 of this consultation report, in 2003 IOSCO published a final report setting out principles for addressing sell-side analyst conflicts of interest. These principles applied to an analyst’s role in both primary and secondary markets and, therefore, have broader application than the topic being examined in this consultation report. However, there are two broad principles of particular relevance.

The first states that mechanisms should exist so that analysts’ research and recommendations are not prejudiced by the business relationships of the firms that employ them. This is intended to address the risk that bias is imparted to an analyst’s research. The principle includes a range of non-binding Guidance for IOSCO members to consider implementing domestically, including requiring firms to establish robust information barriers between analysts and other areas of the firm where a conflict of interest may exist, and prohibiting analysts from participating in investment banking pitches and roadshows. However, despite these existing Guidance, the member survey reflected that there continues to be a risk that, in some jurisdictions, analysts can be placed under pressure to produce favourable research.

The second existing principle states that mechanisms should exist so that analysts’ trading activities or financial interests do not prejudice their research and recommendations. However, as noted above, in some jurisdictions there can be high levels of personal transactions around the time that a securities offering takes place, including by analysts.

IOSCO’s 2007 report considered the types of conflicts of interest which can arise during securities offerings, including pricing and allocations, and provided general guidelines to be taken into account by market participants and regulators. However, the report did not provide any specific targeted Guidance, nor did it consider conflicts of interest and associated conduct risks relating to connected research.

As such, IOSCO considers that additional Guidance is necessary to address the specific potential risks and harms which can arise during the equity capital raising process, as set out above.

What form should the new additional IOSCO Guidance take?

Responses to the survey to C3 members indicated that while there are some clear common characteristics between capital raising processes across different jurisdictions, there are variations in both market practice and the legal and regulatory frameworks governing the process. This means that the severity of the conflicts of interest and associated misconduct risks, and the harm that they can generate, differs across jurisdictions.

IOSCO Guidance would provide IOSCO members with flexibility over whether and how to implement the Guidance domestically, and ensure that any Guidance that they may adopt are appropriate for their legal and regulatory framework and the specific risks arising in their jurisdiction.
Chapter 5- Proposed IOSCO Guidance

This section contains a proposed Guidance with measures that IOSCO members might consider in their regulation of market intermediaries in equity securities offerings. Each measure is intended to address the specific potential risks and harms identified in Section 4.

The Guidance reflects an expectation of high standards of conduct across market intermediaries in the equity capital raising process. This includes the:

- production and distribution of a connected analyst’s views on the issuer;
- pricing of an offering; and
- allocations of securities.

The eight measures, which are grouped by the relevant stage in the capital raising process, address a specific conflict of interest or associated conduct risk identified in Section 4.

Given the significant potential risks and harms these measures are intended to address, IOSCO members are encouraged to consider the extent to which these measures should be implemented in the context of their legal and regulatory framework. Members should also carefully consider the proposed Guidance in the context of existing IOSCO Principles and associated implementing measures of relevance to the capital raising process (see Section 2).

Guidance to address conflicts of interest and pressures on analysts during the formation of their views on an issuer during the pre-offering phase of a capital raising

One of the key priorities for firms during the pre-offering phase\(^\text{16}\) should be to preserve the analyst’s independence and the integrity of their research. Firms should appropriately manage any potential conflicts of interest arising during the formation of the analyst’s views on the offering and the production of research. Where a conflict cannot be appropriately managed, it should be avoided altogether. This will help to ensure that an analyst’s views and research are not compromised or at risk of bias. This will also reduce the likelihood that investors are provided with an inaccurate picture of the issuer’s prospects.

Given the conflicts of interest which can arise during the formation of a connected analyst’s views on an offering, firms should take appropriate steps to support the provision of a wide range of information to investors. This would help to mitigate any conflict of interest and support balanced price discovery.

Measure 1: In the context of pitches to secure a mandate to manage an equities securities offering, regulators should consider requiring firms to take reasonable steps to prevent their analysts from coming under pressure to take a favourable view on the offering from the issuer’s representatives.

\(^{16}\) See Figure 1, page 6. In the earlier stages of the pre-offering phase, analysts will be “unconnected”. Upon the firm being appointed to manage the offering, the analyst becomes a “connected analyst”. Analysts, whether connected or unconnected, are at risk of having their independence jeopardised and the integrity of their views and research comprised or biased.
IOSCO members should consider introducing Guidance which, in the context of a firm’s pitches for underwriting or placing mandates during the ‘pre-offering phase’ (see Figure 1 on page 5 in Section 3), prevent analysts within that firm from being in a position where they could come under pressure to develop a favourable view on the issuer.

The purpose of the Guidance would be to:

(i) prohibit explicit or implicit promises of favourable research coverage; and
(ii) prevent analysts from participating in pitches alongside corporate advisory or investment banking staff within the firm.

To mitigate the risk that an analyst comes under pressure during interactions with the issuer’s representatives in the period before the corporate advisory or investment banking staff within the firm decides to pitch for a mandate and up to the awarding of the mandate, regulators should consider requiring firms to address the following key issues:

(i) whether it is appropriate to allow analysts to answer questions that directly relate to the proposed capital raising transaction, from the issuer or its representatives, or whether questions should only be permitted to be asked by the analyst; and

(ii) in order to assist the analyst in forming a view on the issuer, but recognising the risk of improper influence on the analyst, what is the appropriate subject matter for questions; and

(iii) at what point should interactions cease and, if permitted under local law, recommence.

Paragraphs (i)-(iii) above recognise the powerful commercial incentives for the awarding of mandates and the circumstances in which firms must be acutely aware of the need to manage their conflicts of interest during such interactions. In fact, since it may be difficult for firms to manage such conflicts, where permitted under local law, regulators should consider introducing Guidance which restrict or prevent such interactions. This would have the benefit of reducing or avoiding the risk of soft pressures being placed on analysts, whilst also providing firms with comfort that there is a level playing field across industry.

This Guidance is intended to address the risk that analysts may be put under pressure to have a favourable view of the issuer to secure their firm a position on the syndicate. The Guidance, therefore, helps to address a key underlying conflict of interest which can arise during the development of a connected analyst’s view on an offering. It is aimed at ensuring the independence of the analyst and the integrity of their research.

**Measure 2: Regulators should consider requiring that once an underwriting or placing mandate has been awarded, firms take reasonable steps to prevent a connected analyst’s views and research on the equities securities offering from being improperly influenced and to ensure that the analyst remains independent.**

This Guidance is intended to prevent any improper influence on a connected analyst when forming their views on the issuer and the equities securities offering, once their firm has been awarded a mandate to manage the offering, but before the beginning of the offering phase and release of connected research (see Figure 1 on page 5 in Section 3).
Firms managing an offering should have controls in place which prevent corporate advisory or investment banking staff within the firm from acting in a way which would improperly influence a connected analyst, compromise the objectivity of a connected analyst, and undermine the integrity of connected research and the capital raising process more broadly.

Regulators should consider preventing regulated independent corporate finance advisers to the issuer\textsuperscript{17} from conducting themselves in a way which could compromise the objectivity or an analyst, including improperly influencing or pressuring the analyst.

One example of improperly influencing the connected analyst’s research would be to amend the connected research.

\textbf{Measure 3:} Regulators should consider requiring that, once an underwriting or placing mandate has been awarded, firms have appropriate controls to manage potential conflicts of interest and associated conduct risks arising from connected analysts performing an internal advisory role within the firm in the context of an equity securities offering.

IOSCO members should consider introducing specific Guidance to manage conflicts arising from an analyst performing an internal advisory role within the firm once an underwriting or placing mandate has been awarded (see Figure 1 on page 6 in Section 3).

Regulators should consider requiring firms to consider the nature of the activities to be undertaken by the analyst in performing such a role. Analysts may, for example, provide updates on the general outlook for and investor views on the sector and their views on investor demand. Once their research is released, connected analysts may also support broader investor education. While analysts may undertake these types of activities, regulators should consider requiring firms to have in place appropriate controls that prevent an analyst from performing an internal advisory role in relation to the investment banking function of the firm. They may, for example, interact on administrative matters such as organising meetings with investors for investor education.

The Guidance is particularly relevant in jurisdictions where the views of connected analysts play a prominent role during investor education and initial price discovery. This is because, in such cases, the underlying conflict of interest is exacerbated by the fact that the analyst’s views are a main source of information available to investors during this crucial stage in the capital raising process.

\textbf{Measure 4:} Regulators should consider requiring firms to support the provision of a wide range of independent information to investors in a timely manner, where distribution of such information is permitted under local law.

To mitigate the conflicts of interest which can arise during the production and distribution of a connected analyst’s views on an equities securities offering (see Figure 1 on page 5 in Section 3), firms should consider supporting the provision of a wide range of information to prospective investors early in the equities capital raising process, where permitted.

\textsuperscript{17} Outside of the firm managing the offering.
In the context of an equity IPO, this could include, for example, referring to the official offering document as the primary source of information on the issuer during the offering. Firms should be encouraged to consider whether it would be appropriate for the firm to release a connected analyst’s research on the issuer only once an official offering document has been published.

This could also include helping to facilitate the emergence of more unconnected research in the IPO process, should an interest be expressed by unconnected analysts, and provided the required consents are in place. For example, firms could facilitate access for unconnected analysts to the necessary information required to prepare unconnected research, such as an offering document.

This Guidance is intended to help ensure that a wide range of high quality information is available to investors during investor education. Such information would support the development of a balanced price range to set the parameters for the price formation during a book-build. This would help to mitigate any bias which has been imparted to the views of connected analysts, which can otherwise be a dominant driver of price discovery.

**Guidance to address conflicts of interest during the allocation of securities**

A robust and transparent allocation process is fundamental to the integrity of equity capital markets, helping to ensure confidence amongst both investors and issuers.

While carrying on a mandate to manage a securities offering, a firm is providing a service to its issuer client and, when placing shares, a firm should reflect the interest of its issuer. However, when processing and accepting indications of interest from its investor clients, the firm also has responsibilities to these clients.

When a firm places the shares of its issuer client it should appropriately manage any conflicts of interest between itself and the issuer client or between any two of its clients. The process for allocations should also be transparent, allowing the firm to demonstrate that they have effectively managed any conflicts of interest.

Where any conflicts of interest do arise, it is for the firm to demonstrate that it has appropriately managed the conflict. For instance, where allocations are skewed towards the firm’s own asset management arm, or towards certain investor clients of the firm over others, any potential conflicts of interest in allocations should not compromise the issuer’s interests or unfairly discriminate between its investor clients.

**Measure 5: Regulators should consider requiring firms to maintain an allocation policy that sets out their approach for determining allocations and that provides the issuer with an opportunity to express their preference during the process.**

IOSCO members should consider requiring that, once accepting a mandate to manage an offering on behalf of the issuer client, the firm has in place an allocation policy that sets out the overarching methodology it adopts for determining an allocation of equity securities. As part of this, regulators should consider requiring firms to give the issuer an opportunity to express their preference in the allocation process.
This Guidance provides transparency to the process before the provision of services, ensuring the issuer client can make an informed decision about the firm with which it intends to proceed. An allocation policy that the firm is required to maintain also provides a reference point against which the issuer can assess the quality of service the firm delivered to them post-transaction.

Although not all issuers will necessarily wish to play an active role in this process, providing them with an opportunity to do so promotes transparency and can help to mitigate potential conflicts of interest in the process. Firms engaging the issuer at certain key junctures in the process helps to ensure that the firm takes meaningful steps to involve the issue in the process and provides set points for the issuer to have an opportunity to influence the process, crucially before the allocations are made.

Measure 6: Regulators should consider requiring firms to maintain records of the allocation decisions to demonstrate that any conflicts of interest are appropriately managed.

Regulators should consider requiring firms to record details of allocation decisions made.

The records the firm maintains should include:

- The firm’s overarching allocation policy;
- Where appropriate, the firm’s initial discussion with the issuer client and the specific approach adopted for allocating its shares;
- The allocation orders received from potential investors;
- Any relevant discussions, instructions or preferences provided by the issuer, other members of the syndicate or the firm itself, on the allocation process;
- Details of the final allocation made to each investor.

Through these records, firms would typically be able to demonstrate how any conflicts of interests have been appropriately managed to ensure that the issuer’s interests have not been compromised.

This Guidance is intended to significantly increase the transparency in the allocation process and support regulators in their supervisory activities in this area. The records may also help the firm in monitoring its existing arrangements for determining allocations and in reviewing allocations made.

Guidance to address conflicts of interest in the pricing of securities offerings

Conflicts of interest which may arise between the firm or its other clients and the issuer client must be appropriately managed. This includes any conflicts in relation to possible under-pricing or over-pricing of an offering.

Firms should consider involving the issuer client in and make them aware of any decisions and actions which influence the pricing outcome to ensure that they are made aware of those decisions and actions.
Regulators should consider introducing Guidance which explicitly requires the firm to manage any conflicts of interest in relation to the pricing of an equity securities offering, ensuring that pricing does not reflect their own interests or those of their investor clients in a way which conflicts with the issuer’s interests. Firms should consider providing the issuer with an opportunity to engage in the decisions and actions that can influence the pricing of the securities offering, which may include providing the issuer with key information relevant to pricing as the transaction evolves. In addition, regulators should consider if firms should be required to consider the issuer’s specific preferences, if any, and how they relate to any decisions or actions which influence the price.

In a secondary offering context, where the price of an issuer’s security is already observable on the secondary market and where there is less discretion on the price of the new offering, regulators should consider requiring the firm to take steps to ensure that the issuer’s interests in relation to pricing are not compromised. This includes, for example, ensuring that the bank manages any conflicts of interest that could arise through the hedging strategies and risk management transactions that the firm carries out to mitigate its own underwriting risk. Regulators should consider requiring firms to maintain a record related to how pricing outcomes are developed, how the issuer is involved, and how any conflicts of interest are managed to ensure that the issuer’s interests have not been compromised. This would assist regulators in their supervisory work in this area.

This Guidance is intended to address potential detriment which can arise from the conflict of interest stemming from firms’ efforts to mitigate underwriting risk. It should help to ensure that the issuer’s interests with respect to pricing are not compromised, and that pricing is as efficient as it can be. This would reinforce the benefits intended to be brought about by Measures 1-4, which should also enhance the integrity and efficiency of price formation by ensuring a wider range of high quality information is available to investors.

**Guidance to address conflicts of interest and conduct risks stemming from personal transactions by staff employed within firms managing a securities offering**

Ensuring a high standard of conduct among firms’ employees is crucial to market participants maintaining confidence in capital markets. In a securities offering context, an important aspect of this is that firms managing a securities offering effectively manage or avoid any conflicts of interest between themselves and their clients. This includes any conflicts of interest arising from the conduct of firms’ employees (e.g. investment banking staff and connected analysts), including during personal transactions by those employees.

There is a heightened risk of conflicts where employees involved in a securities offering have access to confidential information on the issuer and undertake personal transactions in the securities of the issuer. Firms should be particularly careful in these situations, and ensure that employees undertaking personal transactions do not misuse their position or any
confidential information they have acquired through their position to the detriment of the issuer.

**Measure 8:** In the context of a securities offering, regulators should consider requiring firms to prevent any employees who have access to confidential information on the issuer from entering into or causing any personal transactions in situations where it involves misuse or improper disclosure of the confidential information. Regulators should also consider requiring firms to prevent any employees from entering into personal transactions where it otherwise gives rise to any conflicts of interest.

This Guidance is intended to address any conflicts of interests arising from personal transactions by employees of firms managing a securities offering, which can have a detrimental impact on the issuer client in a capital raising context. As described in Section 3, this can be of particular relevance to connected analysts and investment banking staff involved in an IPO and secondary offering.

Firms and employees should consider whether the information that some employees have access to amounts to market sensitive or inside information, and should be mindful of their obligations under the relevant market abuse regime, i.e. whether employees are able or if it would be appropriate for employees to enter into a personal transaction in the offering being managed by the firm.

**Question:** Do you agree that the Guidance set out in this section of the Consultation Report are appropriate to address the potential conflicts of interest and associated conduct risks arising in the equity capital raising process and resulting harm identified in Section 3?
Chapter 6- Conclusion and next steps

The Guidance proposed above is intended to address some significant potential conflicts of interest and associated misconduct which can arise at various stages of the equity capital raising process. If implemented, the Guidance should bring about material improvements to the process. This includes enhancing the:

- range and quality of timely information that is made available to investors during the process;
- transparency of allocations; and, therefore the
- efficiency and integrity of overall process, boosting investor confidence and making capital markets a more effective route for issuers to raise finance.

This would help to ensure that capital markets continue to have a positive impact on the global economy.
ANNEX 1 - Participants in the equity capital raising process

Across a number of jurisdictions, the main participants typically involved in the equity capital raising process are as follows:

- **Syndicate banks/stockbrokers**: These firms provide underwriting or placing services to the issuer and advise on key elements of the transaction (e.g. pricing and timing of the offering) and place the securities with investors. This is a separate advisory service to the one provided by independent (third party) corporate finance advisers.

- **Connected analysts**: These are research analysts who are employed by the syndicate banks or stockbroking firm. Connected analysts are typically tasked with producing research to provide investors with their views on the issuer, and in some jurisdictions, to support investor education and initial price discovery. These analysts also play an internal facing advisory role for the investment bank or firm, focusing on assessing whether it should participate in the IPO and also conduct ongoing due diligence as the transaction evolves.

- **Legal advisers**: These advisers provide legal advice to the issuer on the transaction, typically assisting in drafting contracts with syndicate banks; drafting and verifying the information to be included in the prospectus or offering document; and making disclosures more generally. Syndicate banks and stockbroker firms will also have lawyers to act on their behalf, often to review the offering document or prospectus and conduct due diligence.

- **Accountancy and audit firms**: These firms express the audit opinion on the issuer’s financial statements to be submitted to the competent authority.

In some jurisdictions, the following participants can also be involved:

- **Independent corporate finance advisers**: The primary role of these firms is to act as the intermediary between the issuer and firms managing the securities offering. They may be involved in the selection of the bank(s) and have oversight of them during the IPO process. Corporate finance advisers may also advise on different financing options; deal structure and timing; pricing and allocations. This is a separate advisory service to the one provided by firms managing the offering.

- **Financial due diligence consultant**: This will be an independent adviser that issues an independent financial due diligence report to the issuer and/or underwriter.

- **Ballotter**: These will conduct ballots for retail offers when oversubscribed.

- **Other advisers**: The issuer may engage a wider range of advisers, including for industrial relations, communications and strategy.

- **Listing/payment/issuing (or settlement, transfer and paying) agent**: This firm ensures that the securities are admitted on the exchange’s book-entry system on time and acts as the listing agent. This is generally one of the underwriters.
ANNEX 2 - Legal and regulatory frameworks governing the capital raising process and controls and policies in place within firms to manage conflicts of interest

There are a variety of regulatory and legal frameworks governing various aspects of the capital raising process across different jurisdictions. We have broken these down by theme, reflecting the conflicts of interest and associated misconduct risks identified in the UK FCA and ASIC’s recent work, as referenced in Section 1 of this CP. This includes a description of the internal policies that firms typically have in place to manage conflicts of interest and meet certain regulatory or legal requirements.

Production and distribution of connected research

All jurisdictions have a regulatory framework that is intended to preserve the independence of analysts during the production and distribution of research. The most notable difference across these jurisdictions is that, while some have specific legal requirements or rules that expressly govern the production and distribution of investment research (including connected research used in securities offerings), others currently rely on broader legal and regulatory requirements (including statutory obligations) regarding conflicts of interest, the impartiality of investment advice and a disclosure regime.

In a number of jurisdictions, analysts are prohibited from attending pitches or otherwise participating in efforts to solicit investment banking business. There is an exemption in the US under the Jump Start Our Business (JOBS) Act for meetings with an Emerging Growth Company. There is also an exemption in the EU for producers of research that is not subject to such prescriptive conflicts of interest provisions provided that it is labelled as a marketing communication, which is most commonly produced on smaller IPOs.

A number of jurisdictions are in the process of enhancing their regulatory framework for the production of connected research. ASIC is currently consulting on introducing additional guidance on the management of conflicts of interest which can arise during the production of connected research, and on the structure and funding of the research function. The UK FCA has also recently consulted on similar enhancements to its existing investment research regime, intended to clarify its expectations under its current guidance on analysts’ involvement in pitches. In addition, the EU’s Markets in Financial Instruments Directive introduced a requirement in 2007 for firms to maintain physical separation between analysts and areas of the firm whose interests may conflict with those of the analyst. In the United States, FINRA recently adopted extensive rules that foster objectivity and transparency in research reports, to provide investors with reliable information upon which to make investment decisions.

To manage and avoid conflicts of interest during the development of a connected analyst’s views on an offering, firms have typically documented compliance procedures, physical and structural segregation arrangements and information barriers between analysts and other areas of the firm, e.g. corporate advisory or investment banking staff. In some cases, firms impose physical barriers and conduct surveillance of communications. Firms seek to ensure that communications between analysts and investment banking staff are monitored or chaperoned by legal and compliance staff. Where regulatory provisions are quite specific, firms will often
establish controls directly in line with those requirements. This includes allowing the review of draft reports for fact checking only, ensuring employees declare compliance with the relevant requirements, wall-crossings, employee trading restrictions and ensuring supervisory analysts review and approve research before it is published.

**Provision of information during the capital raising process**

Most jurisdictions have specific rules governing the timing and content of information included in the prospectus, which issuers are required to publish ahead of their shares being admitted to trading. Under the current EU prospectus regime, issuers are not required to produce a prospectus in situations where they are seeking to raise capital of less than 10% of their existing shares admitted to trading. However, this threshold will increase from 10% to 20% once the new EU Prospectus Regulation comes into effect.

It is also common for jurisdictions to have overarching rules requiring firms to manage any conflicts of interest and rules ensuring that firms prevent flows of confidential and price sensitive information between their corporate advisory team, corporate finance advisory team and other areas of the business.

Similarly, a number of jurisdictions have overarching antifraud and anti-manipulation provisions that prohibit misstatements and misleading omission of material facts, and fraudulent and manipulative acts and practices during the IPO process. Some have similar provisions which seek to ensure any information and representations received from the issuer, and made to the public are true, accurate, complete and not misleading.

Some jurisdictions plan to enhance their framework in this area. The UK FCA has proposed new rules which would seek to ensure that, during an equity IPO, an approved prospectus or registration document is published, and unconnected analysts have access to the issuer’s management, before any connected research is released. This is in addition to its proposed guidance outlined earlier. In Canada, the legal framework is contained in securities legislation rather than IIROC's own rules. IIROC reported that the focus will be on enhancing the existing framework specifically as it applies to investment dealer-only matters, i.e. confidential information containment, restricted securities and grey lists, information barriers, due diligence and fair allocation.

**Allocations of securities**

Regulatory requirements specifically for the allocations process, as distinct from requirements governing the prevention and management of conflicts of interest generally, vary greatly across jurisdictions. They include: a requirement for firms to maintain an allocation policy setting out the approach they adopt for determining allocations; a requirement for allocations to be fair, equitable and transparent; IPOs to include a mandatory public subscription tranche to facilitate retail participation; allocations by drawing lots (retail subscriptions); restrictions on who may receive IPO allocations; requirements with respect to allocations, pricing and trading of IPOs to prevent problematic practices, such as quid pro quo allocations; clawback mechanisms to increase public allocations in oversubscriptions; minimum shareholding spread post-IPO by public shareholders; limitations on subscriptions by connected parties; and mandatory disclosure of the volume of the public offering and, if applicable, the size of allocations to connected subscribers.
Specific plans to enhance the existing regulatory framework include:

(i) Singapore has introduced a requirement that all primary-listed Mainboard IPOs must allocate at least 5% or $50 million, whichever is the lower of the offer size, to the public subscription tranche.

(ii) ASIC have recently launched a review of allocation practices in the Australian market. Based on the results of the review, the regulator will consider whether updates to the relevant regulatory guidance are required.

(iii) IIROC is looking at specifically prohibiting certain allocation practices (practices that are not currently prohibited under general conflicts of interest management and avoidance requirements), including dealers withholding securities in a public offering for their own employees’ benefit and dealers rewarding persons who are in a position to direct future business to the dealer with preferential allocations.

(iv) At an EU level, MiFID II legislation has recently introduced more targeted principles-based provisions governing underwriting and placing services. For example, firms will be required to do the following:
   • Inform the issuer of the various financing alternatives available with the firm prior to accepting a mandate to manage an offering;
   • Have in place a centralised process to identify all potential conflicts of interest arising from other activities of the firm or group, and implement appropriate management procedures;
   • Secure the issuer’s agreement to the proposed allocation per type of investor for the transaction in accordance with its allocation policy; and
   • Maintain records of allocation decisions taken at each stage of the capital raising process, and to justify the final allocation made to each investor client.

Firms across various jurisdictions generally maintain policies on allocations and conflicts of interest. Some firms do carry out post-transaction allocation reviews but this does not appear to be common practice. In some jurisdictions, firms are required to assign staff to review all transactions relating to the firm’s investment banking or securities business. Some firms may use a risk-based review approach to comply with these requirements. In Switzerland, after close of the transaction the lead manager must disclose the volume of the public offering, and if applicable, the size of allocations to groups of subscribers with a special relationship to the issuer as well as any exercise of the overallotment option.

Other controls that firms may use to meet their regulatory obligations and to manage conflicts of interests and conduct risk in the allocation process include:

(i) Keeping appropriate records (a requirement in some jurisdictions) such as records showing when, to whom and how securities were allocated in a particular transaction and records evidencing supervisory reviews to verify proper use of allocations policies;

(ii) Staff training on conflicts of interest (including reporting);
(iii) Information barriers between functions of a firm that determine allocations and other areas of the firm such as secondary trading; and

(iv) Certifications as to professional competence.

In some jurisdictions, however, allocation policies have been found to not necessarily translate into good allocation practices. In particular, the UK FCA found a clear relationship between the revenue generated by the investor to the firm through other business lines and allocations, despite the vast majority of firms’ allocation policies explicitly prohibiting quid-pro-quo arrangements. The analysis conducted by the FCA controlled for the various bid and bidder characteristics that could otherwise explain the allocation made.

In the context of secondary offerings, whilst the conflicts of interest and associated misconduct risks in the process depend on the type of the offering, the regulatory requirements and controls firms have in place to meet their regulatory obligations are largely the same as in the context of IPOs.